Search

Immunobiology / Immunotherapy of H&N Cancer

B046

ANTI-OX-40 (MEDI6469) PRIOR TO DEFINITIVE SURGICAL RESECTION IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunobiology / Immunotherapy of H&N Cancer

R. Bryan Bell, MD, DDS, FACS1, Rom S Leidner, MD1, Zipei Feng, MD, PhD2, Rebekka Duhen, PhD1, Yoshi Koguchi, PhD1, Carlo Bifulco, MD1, Bernard A Fox, PhD1, Brendan Curti, MD1, Andrew D Weinberg, PhD1

1Earle A. Chiles Research Institute at Providence Cancer Center, 2Oregon Health & Science University


B047

THE ROLE OF TLR3 SIGNALING IN CHEMORESISTANCE OF HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunobiology / Immunotherapy of H&N Cancer

Hui-Ching Chuang, MD, PhD

Kaoshiung Chang Gung Memorial Hospital


B048

LOSS OF PROTECTIVE CD169 MACROPHAGES IN LYMPH NODES WITH METASTATIC SQUAMOUS CELL CARCINOMA WITH PRESERVATION IN ADJACENT NEGATIVE DRAINING LYMPH NODES

Immunobiology / Immunotherapy of H&N Cancer

Michael C Topf, MD, Christopher M Shumrick, BS, Madalina Tuluc, MD, David M Cognetti, MD, Joseph M Curry, MD, Adam Luginbuhl, MD

Thomas Jefferson University Hospital


B049

CETUXIMAB AND CISPLATIN EFFECTS ON OROSPHERE FORMATION AND GENE EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) CELLS: THE POTENTIAL FOR A PROGNOSTIC BIOMARKER

Immunobiology / Immunotherapy of H&N Cancer

Valeda Yong, BA1, Lechuang Chen, MD, PhD2, Ashlee Jeter, BS2, Chad Zender, MD, FACS3, Ge Jin, PhD2, Aaron Weinberg, DMD, PhD2

1Case Western Reserve University School of Medicine, 2Case Western Reserve School of Dental Medicine - Biological Sciences, 3University Hospitals Cleveland Medical Center - ENT Institute


S032

PD-1 BLOCKADE PREVENTS THE DEVELOPMENT OF ORAL SQUAMOUS CELL CARCINOMA FROM CARCINOGEN-INDUCED PREMALIGNANT LESIONS

Immunobiology / Immunotherapy of H&N Cancer

Jin Wang1, Bingbing Wang1, Xiaoyuan Zhu1, Tongxin Xie1, Adel K El-Naggar2, Jeffrey N Myers1, Carlos Caulin1

1Departments of Head and Neck surgery,The University of Texas MD Anderson Cancer Center, 2Department of Pathology, The University of Texas MD Anderson Cancer Center


S033

POST-OPERATIVE IMMUNE CHECKPOINT BLOCKADE TO PREVENT CANCER RECURRENCE IN THE SURGICAL WOUND

Immunobiology / Immunotherapy of H&N Cancer

Nayeon Choi, MD, Hangyul Kim, MD, Jungjoo Lee, MD, Youngsang Cho, MD, Boyoung Kim, MD, Han-Sin Jeong, MD, PhD

Samsung Medical Center


S074

AVELUMAB (ANTI-PD-L1) IN COMBINATION WITH CHEMORADIOTHERAPY (CRT) VS CRT IN FIRST-LINE TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LA-SCCHN): JAVELIN HEAD AND NECK 100 PHASE 3 TRIAL

Immunobiology / Immunotherapy of H&N Cancer

Nancy L Lee, MD1, Robert L Ferris, MD, PhD2, Kevin J Harrington, MD3, Robert I Haddad, MD4, Jean Bourhis, MD, PhD5, Makoto Tahara, MD, PhD6, Margarida Geraldes, PhD7, Dimitry S.A Nuyten, MD, PhD7, Zelanna Goldberg, MD7, Ezra Cohen, MD8

1Memorial Sloan Kettering Cancer Center, 2University of Pittsburgh Medical Center, 3The Institute of Cancer Research Chester Beatty Laboratories, 4Dana-Farber Cancer Institute, Harvard Medical School, 5Centre Hospitalier Universitaire Vaudois (CHUV) University of Lausanne, 6National Cancer Center Hospital East, 7Pfizer Inc., 8Moores Cancer Center, University of California